FREMONT, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, is furthering its mission to advance the next generation of high parameter cell analysis by continuing to have an active presence at key industry events worldwide. The company’s Full Spectrum Profiling™ (FSP™) technology that streamlines workflows, accelerates discoveries and maximizes efficiency will be front and center at both the European Society for Clinical Cell Analysis’ (ESCCA) 2023 Conference in September and the 38^th International Clinical Cytometry (ICCS) Meeting & Course in October.

Cytek will be on hand at ESCCA 2023 in Utrecht, the Netherlands from September 27-30 to showcase its complete cell analysis solutions that enable scientists to advance their research, gain deeper insights, and fast-track discovery. Attended by hematologists, immunologists, microbiologists, laboratory medicine specialists, researchers, technicians, laboratory managers and staff, and pharma biologists related to clinically applied flow cytometry, ESCCA provides a forum for education and scientific exchange.

At the conference, Dr. Manuel Ramirez, Head of Oncology Research Lab for Madrid’s Hospital Infantil Universitario Niño Jesús, will lead a symposium focused on the process of designing and optimizing a 24-color B cell panel for use with childhood B-ALL, including considerations for choice of fluorochromes. Dr. Ramirez will share data that points to the fact that the unique full spectrum approach employed by the Cytek^® Northern Lights™-CLC flow cytometer, complemented by a novel optical design and robust unmixing algorithm, increases laboratory efficiency by allowing more information to be gleaned from a single tube – saving time and resources. The symposium will take place on Thursday, September 28, 2023, from 3:00-3:30 p.m. CET.

“Cancer treatment is an ever-evolving field, with clinical researchers and clinicians constantly striving to improve diagnostics and treatment,” said Dr. Ramirez. “While flow cytometers have become a standard tool in our arsenal, Cytek is truly shaping the future of what is possible through cell analysis with its revolutionary spectral technologies.”

The ICCS Annual Meeting & Course in New Orleans seeks to help participants increase their knowledge of current tools and technologies available for patient sample analysis, better understand the accepted methodologies and benchmarks for patient sample analysis and diagnosis, and increase their competence in using analytical software applications. To that end, Cytek will conduct a ‘Lunch and Learn’ presentation that focuses on the critical roles panel design and assay optimization play in laboratory developed tests (LTDs). Hosted by Paul K. Wallace, Ph.D., Professor Emeritus at the Roswell Park Comprehensive Cancer Center in Buffalo, New York, this presentation will take place on Sunday, October 1, 2023, at 12:00 p.m. CT.

For more information, please visit www.cytekbio.com.

About Cytek Biosciences, Inc.

Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s FSP platform includes its core instruments, the Aurora and Northern Lights™ systems; its cell sorter, the Aurora CS; the flow cytometer and imaging products under the Amnis^® and Guava^® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.

Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use in China and the European Union).

Cytek, Full Spectrum Profiling, FSP, Northern Lights, Amnis and Guava are trademarks of Cytek Biosciences, Inc.

In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “might," "will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding Cytek’s mission, product plans and business strategies. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management. These statements also deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to global economic and market conditions; Cytek’s dependence on certain sole and single source suppliers; competition; market acceptance of Cytek’s current and potential products; Cytek’s ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and retain key employees; Cytek’s ability to maintain, protect and enhance its intellectual property; and Cytek’s ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations. You should refer to the section entitled “Risk Factors” set forth in Cytek’s Quarterly Report on Form 10-Q filed with the SEC on August 8, 2023 and other filings Cytek Biosciences makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek’s forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are based on information available to Cytek as of the date hereof, and Cytek disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek’s views as of any date subsequent to the date of this press release.

Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Contact:
Paul Goodson
Head of Investor Relations
Cytek Biosciences
This email address is being protected from spambots. You need JavaScript enabled to view it.